Pharco D receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pharming Group NV (PHAR)
Track today's live Pharming Group (PHAR) share price, performance and key data on this page with our current Amsterdam:PHAR stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Pharming Group share price on the Amsterdam exchange. Use the dropdown to switch exchange for the PHAR share price, head to our technical summary section, which provides analysis on Pharming Group share price buy/sell indicators using real-time data (or discuss the Pharming Group (PHAR) stock price today with other investors in the Pharming Group AS share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current AS:PHAR share price (ISIN: NL0010391025) to enhance your trading decisions with our free investment tools and resources.
What Is the Pharming Group NV Share Price Today?
The Pharming Group share price today is 1.128.
What Is the Stock Symbol for Pharming Group NV
The stock symbol (or 'ticker') for Pharming Group NV is "PHAR."
What Stock Exchange Does Pharming Group NV Trade On?
Pharming Group NV is listed and trades on the Amsterdam stock exchange.
Is Pharming Group NV a Good Stock to Buy?
Determining whether Pharming Group (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current AS:PHAR share price (ISIN: NL0010391025) to enhance your trading decisions with our free investment tools and resources.
What Is the Pharming Group NV Share Price Today?
The Pharming Group share price today is 1.128.
What Is the Stock Symbol for Pharming Group NV
The stock symbol (or 'ticker') for Pharming Group NV is "PHAR."
What Stock Exchange Does Pharming Group NV Trade On?
Pharming Group NV is listed and trades on the Amsterdam stock exchange.
Is Pharming Group NV a Good Stock to Buy?
Determining whether Pharming Group (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Amsterdam
Currency in EUR
1.128
+0.039(+3.53%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.088
1.149
52 wk Range
0.820
1.818
PHAR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.0881.149
52 wk Range
0.8201.818
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PHAR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
2.214
Upside
+96.31%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Why is Pharming stock climbing today?- Investing.com
- Pharco D receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 2.214
(+96.31% Upside)
Pharming Group NV Earnings Call Summary for Q3/2026
- Pharming Q3 revenue rose 21% YoY to $117.6M, beating forecasts by 13.58%; operating profit surged 89% to $29.9M with shares jumping 18.97%.
- RUCONEST revenue grew 14% to $93.8M as U.S. demand stabilized; Joenja revenue climbed 58% to $23.8M with pediatric expansion expected in Q4.
- Full-year 2026 revenue guidance tightened to $380M-$390M; operating expenses lowered to $310M-$315M reflecting $9M in structural savings.
- Company operates under interim co-CEOs during permanent search; cash position strengthened to $190.9M, eliminating near-term financing needs.
- CVID study data expected November 2026; napazimone FALCON trial enrollment continues with completion targeted for H1 2027 amid HAE competition risks.
Last Updated: 27/10/2026, 13:28
Read Full TranscriptEarnings
Latest Release
22/10/2026
EPS / Forecast
-- / --
Revenue / Forecast
117.6M / 103.54M
Compare PHAR to Peers and Sector
Metrics to compare | PHAR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHARPeersSector | |
|---|---|---|---|---|
P/E Ratio | 35.6x | −1.5x | −0.3x | |
PEG Ratio | 0.00 | 0.13 | 0.00 | |
Price/Book | 3.0x | 1.7x | 2.6x | |
Price / LTM Sales | 2.2x | 4.3x | 2.8x | |
Upside (Analyst Target) | 95.9% | 143.3% | 66.4% | |
Fair Value Upside | Unlock | 9.2% | 9.0% | Unlock |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Pharming Group (Amsterdam: PHAR) Share Price Today?
The Pharming Group stock price today is 1.128 EUR.
What Stock Exchange Does Pharming Group (PHAR) Trade On?
Pharming Group is listed and trades on the Amsterdam Stock Exchange.
What Is the Ticker (Stock Symbol) for Pharming Group?
The stock symbol (also called a 'ticker') for Pharming Group is "PHAR."
What Is the Current Pharming Group Market Capitalisation?
As of today, Pharming Group (Amsterdam: PHAR) market cap is 799.090M EUR.
What Is Pharming Group's (PHAR) Earnings Per Share (TTM)?
The Pharming Group EPS is currently 0.029 (Trailing Twelve Months).
Is PHAR a Buy or Sell From a Technical Analyst Perspective?
Based on today's Pharming Group moving averages and other technical indicators, the daily buy/sell signal for PHAR stock is Strong Buy.
How Many Times Has Pharming Group Stock Split?
Pharming Group has split 2 times. (See the PHAR stock split history page for full effective split date and price information.)
How Many Employees Does Pharming Group Have?
Pharming Group has 407 employees, based on their latest Companies House report.
What is the current trading status of Pharming Group (Amsterdam: PHAR)?
As of 02/11/2026, Pharming Group (PHAR) is trading at a share price of 1.128 EUR, with a previous close of 1.090 EUR. The stock has fluctuated within a day range of 1.088 EUR to 1.149 EUR, while its 52-week range spans from 0.820 EUR to 1.818 EUR.
What Is Pharming Group (PHAR) Price Target According to Analysts?
The average 12-month price target for Pharming Group is 2.214 EUR, with a high estimate of 2.45014755 EUR and a low estimate of 2.00035769 EUR. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +96.31% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.